Clinical trials: Circulating Tumor DNA (ctDNA)
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the…
- Conditions
- Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT04574635
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Ovarian Cancer
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
To analyze the proportion of hereditary tumors in ovarian cancer patients in China, as well as the spectrum of variations; the ctDNA characteristics in patients with ovarian cancer; the correlation between the clonal status of…
- Trial name
- NCT03614689
- Where
- 6 sites in China
- Volunteers
- 104 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Oropharynx Squamous Cell Carcinoma
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
SURVEILLE-HPV - A new post therapeutic surveillance strategy for HPV-driven oropharyngeal cancer based on HPV Circulating DNA measures.
- Trial name
- SURVEILLE-HPV (NCT05582122)
- Testing
- HPV16 Ct-DNA dosing
- Where
- 16 sites in France
- Volunteers
- 420 people
- Sponsor
- UNICANCER
Sarcoma
Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
A tissue biopsy is currently the only clinical test or procedure that is able to confirm the initial diagnosis of soft tissue or metastatic sarcoma and evaluate its progress during treatment.
- Trial name
- NCT03896620
- Testing
- Preoperative RT, Postoperative RT, Chemotherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Medical College of Wisconsin
Renal Cancer
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as…
- Trial name
- KIDNEY-PAGER (NCT06145139)
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Primary Mediastinal Large B-cell Lymphoma
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)
The purpose of this study is to compare the predictive value in terms of specificity of circulating tumor DNA (ctDNA) and positron emission computed tomography (PET-CT) after 2 cycles of chemotherapy (C2), on the probability of…
- Trial name
- CAMIL (NCT04824950)
- Testing
- Circulating tumor DNA monitoring
- Where
- 2 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Henri Becquerel
Ovarian Cancer
Study of Circulating Tumoral DNA in Ovarian Cancer
Circulating tumor DNA detection and quantification in patients with ovarian cancer.
- Trial name
- NCT01350908
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Institut Curie
Melanoma
Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)
This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgery Study participants will complete a ctDNA test within 4 weeks…
- Trial name
- NCT05736523
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Epithelial Ovarian Cancer
Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease
Blood samples and Tumor tissue will be collected at certain timepoints and will be tested.
- Trial name
- NCT05212779
- Testing
- Signatera testing, Altera Testing
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Immunotherapy, Cervical Cancer
Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions
Immunotherapy is the main option for advanced, recurrent and metastatic cervical cancer. However, due to the complex interaction between the immune system and tumors, there is still a lack of effective markers for immunotherapy.
- Conditions
- Immunotherapy, Cervical Cancer, CtDNA, Biomarker
- Trial name
- NCT06649838
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Adenocarcinoma, Pancreatic Cysts
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
This multicenter randomized trial aims to primarily assess and compare the functional recovery of patients who undergo open versus robotic pancreaticoduodenectomy for benign and malignant lesions of the head of the pancreas.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cysts, Pancreatic Endocrine Tumors, Chronic Pancreatitis
- Trial name
- PORTAL (NCT04400357)
- Testing
- Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Ruijin Hospital
Melanoma, Skin Cancer
Circulating Tumor DNA in Melanoma Patients
The aim of this prospective clinical study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma.
- Trial name
- ctDNA (NCT07422805)
- Testing
- Blood Sampling for ctDNA Analysis
- Where
- Slovenia
- Volunteers
- 176 people
- Sponsor
- Institute of Oncology Ljubljana
Hepatocellular Carcinoma
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer.
- Trial name
- REMNANT (NCT05375370)
- Testing
- circulating tumor DNA dosage
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA)
TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort
Purpose of the Study: Bile duct cancers are rare and aggressive. About 250 new cases are diagnosed each year in Denmark. These cancers are difficult to detect early, so only about 20% of patients can have surgery when diagnosed.
- Conditions
- Biliary Tract Cancer (BTC), Biliary Tract Cancer (CCA), Gall Bladder Cancer, Biliary Tract Cancers (BTC)
- Trial name
- TRACE-BTC (NCT07454486)
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Aarhus University Hospital
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Colorectal Cancer
Influence of the Surgical Technique Used for Colectomies on the Concentration of Circulating Tumor DNA and the Presence of Circulating Tumor Cells: Comparison of the "no Touch" Technic With Either First Clamping of the Mesenteric Vessels or First Mobilization of the Tumor Followed by Clamping.
Colectomy is the most commonly used therapeutic approach for the treatment of non-metastatic colorectal cancer. This approach is generally very effective however the rate of recurrence and the appearance of metachronous…
- Trial name
- ADNCHIR (NCT03809403)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
Circulating Tumor DNA After Neoadjuvant Chemotherapy
Trial assessing the prognostic value of ctDNA mutations from samples taken sequentially in patients with invasive breast cancer initially treated with neoadjuvant chemotherapy and whose tumor is not in complete histological…
- Trial name
- ALIENOR (NCT03357120)
- Testing
- Follow-up after neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Institut Bergonié
Peritoneal Carcinomatosis
Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC
PIPADN is a pilot monocentric, study with a total duration of 42 months. The purpose of this study is to describe the variation of plasma ctDNA concentration between the 1st and the 3rd PIPAC session in patients with peritoneal…
- Trial name
- PIPADN (NCT04766502)
- Testing
- Blood sample (20 ml) and EORTC QLQC30 survey
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut de Cancérologie de Lorraine
Pancreatic Neoplasm, Pancreas Cancer
MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer
Developing a characteristic ctDNA methylation panel for pancreatic ductal adenocarcinoma and establishing an intelligent diagnostic and dynamic monitoring model based on ctDNA methylation.
- Trial name
- NCT07045571
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Yingbin Liu, MD, PhD, FACS
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar